|
|
||||||||
Departmet of Radiology, Duke University Medical Center, Durham, North Carolina
Correspondence: For correspondence or reprints contact: R. Edward Coleman, MD, Department of Radiology, Duke University Medical Center, 1419 Duke N., Box 3949, Durham, NC 27710.
ABSTRACT
An estimated 180,000 new cases of lung cancer will be diagnosed in the U.S. this year, and lung cancer accounts for approximately 25% of all cancer deaths. Most lung cancers are initially detected on chest radiographs, but many benign lesions have radiologic characteristics similar to malignant lesions. Thus, additional studies are required for further evaluation. CT is most frequently used to provide additional anatomic and morphologic information about lesions, but it is limited in distinguishing between benign and malignant abnormalities. Because of the indeterminate results obtained from anatomic images, biopsy procedures, including thoracoscopy and thoracotomy, may be used even though one half of the lesions removed are benign and do not need to be removed. Fluorodeoxyglucose (FDG) PET imaging provides physiologic and metabolic information that characterizes lesions that are indeterminate by CT, accurately stages the distribution of lung cancer and provides prognostic information. FDG PET imaging takes advantage of the increased accumulation of FDG in transformed cells and is sensitive (
95%) to the detection of cancer in patients who have indeterminate lesions on CT. The specificity (
85%) of PET imaging is slightly less than its sensitivity because some inflammatory processes, such as active granulomatous infections, avidly accumulate FDG. The high negative predictive value of PET suggests that lesions considered negative on the study are benign, biopsy is not needed and radiographic follow-up is recommended. Several studies have documented the increased accuracy of PET compared with CT in the evaluation of the hilar and mediastinal lymph-node status in patients with lung cancer. Whole-body PET studies detect metastatic disease that is unsuspected by conventional imaging and demonstrate some of the anatomic abnormalities detected by CT to be benign lesions. Management changes have been reported in up to 41% of patients on the basis of the results of whole-body studies.
Key Words: cancer fluorodeoxyglucose PET diagnosis staging
FOOTNOTES
* NOTE: FOR CE CREDIT, YOU CAN ACCESS THIS ARTICLE ON THE SNM WEB SITE (http://www.snm.org) UNTIL NOVEMBER 1999.
This article has been cited by other articles:
![]() |
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend PET/CT: Form and Function Radiology, February 1, 2007; 242(2): 360 - 385. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.J. Kim, B.J. Lee, S.J. Kim, W.-Y. Shim, S.K. Baik, and M. Sunwoo Tongue Abscess Mimicking Neoplasia AJNR Am. J. Neuroradiol., November 1, 2006; 27(10): 2202 - 2203. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Acker and S. C. Burrell Utility of 18F-FDG PET in Evaluating Cancers of Lung J. Nucl. Med. Technol., June 1, 2005; 33(2): 69 - 74. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ishimori, P. V. Patel, and R. L. Wahl Detection of Unexpected Additional Primary Malignancies with PET/CT J. Nucl. Med., May 1, 2005; 46(5): 752 - 757. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Y.-I. Lee, J. Yu, S.-S. Chang, R. Fawwaz, and M. V. Parisien Diagnostic Value and Limitations of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Cartilaginous Tumors of Bone J. Bone Joint Surg. Am., December 1, 2004; 86(12): 2677 - 2685. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Nomori, K. Watanabe, T. Ohtsuka, T. Naruke, K. Suemasu, T. Kobayashi, and K. Uno Fluorine 18-tagged fluorodeoxyglucose positron emission tomographic scanning to predict lymph node metastasis, invasiveness, or both, in clinical T1 N0 M0 lung adenocarcinoma J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 396 - 401. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Agress Jr and B. Z. Cooper Detection of Clinically Unexpected Malignant and Premalignant Tumors with Whole-Body FDG PET: Histopathologic Comparison Radiology, February 1, 2004; 230(2): 417 - 422. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tatsumi, C. Cohade, Y. Nakamoto, and R. L. Wahl Fluorodeoxyglucose Uptake in the Aortic Wall at PET/CT: Possible Finding for Active Atherosclerosis Radiology, December 1, 2003; 229(3): 831 - 837. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Demura, T. Tsuchida, T. Ishizaki, S. Mizuno, Y. Totani, S. Ameshima, I. Miyamori, M. Sasaki, and Y. Yonekura 18F-FDG Accumulation with PET for Differentiation Between Benign and Malignant Lesions in the Thorax J. Nucl. Med., April 1, 2003; 44(4): 540 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Mac Manus, R. J. Hicks, J. P. Matthews, A. McKenzie, D. Rischin, E. K. Salminen, and D. L. Ball Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non-Small-Cell Lung Cancer J. Clin. Oncol., April 1, 2003; 21(7): 1285 - 1292. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Prenzel, S. P. Monig, J. M. Sinning, S. E. Baldus, H.-G. Brochhagen, P. M. Schneider, and A. H. Holscher Lymph Node Size and Metastatic Infiltration in Non-small Cell Lung Cancer Chest, February 1, 2003; 123(2): 463 - 467. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Cetinkaya, A. Turna, P. Yildiz, R. Dodurgali, M. A. Bedirhan, A. Gurses, and V. Yilmaz Comparison of clinical and surgical-pathologic staging of the patients with non-small cell lung carcinoma Eur. J. Cardiothorac. Surg., December 1, 2002; 22(6): 1000 - 1005. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Seltzer, C. S. Yap, D. H. Silverman, J. Meta, C. Schiepers, M. E. Phelps, S. S. Gambhir, J. Rao, P. E. Valk, and J. Czernin The Impact of PET on the Management of Lung Cancer: The Referring Physician's Perspective J. Nucl. Med., June 1, 2002; 43(6): 752 - 756. [Abstract] [Full Text] [PDF] |
||||
![]() |
A G Pitman, R J Hicks, D S Binns, R E Ware, V Kalff, A F McKenzie, D L Ball, and M P MacManus Performance of sodium iodide based 18F-fluorodeoxyglucose positron emission tomography in the characterization of indeterminate pulmonary nodules or masses Br. J. Radiol., February 1, 2002; 75(890): 114 - 121. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lee, J. M. Aronchick, and A. Alavi Accuracy of F-18 Fluorodeoxyglucose Positron Emission Tomography for the Evaluation of Malignancy in Patients Presenting With New Lung Abnormalities : A Retrospective Review Chest, December 1, 2001; 120(6): 1791 - 1797. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Mouroux, N. Venissac, and M. Alifano Combined video-assisted mediastinoscopy and video-assisted thoracoscopy in the management of lung cancer Ann. Thorac. Surg., November 1, 2001; 72(5): 1698 - 1704. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Hicks, V. Kalff, M. P. MacManus, R. E. Ware, A. Hogg, A. F. McKenzie, J. P. Matthews, and D. L. Ball 18F-FDG PET Provides High-Impact and Powerful Prognostic Stratification in Staging Newly Diagnosed Non-Small Cell Lung Cancer J. Nucl. Med., November 1, 2001; 42(11): 1596 - 1604. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Hicks, V. Kalff, M. P. MacManus, R. E. Ware, A. F. McKenzie, J. P. Matthews, and D. L. Ball The Utility of 18F-FDG PET for Suspected Recurrent Non-Small Cell Lung Cancer After Potentially Curative Therapy: Impact on Management and Prognostic Stratification J. Nucl. Med., November 1, 2001; 42(11): 1605 - 1613. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Komaki, M. H. Chasen, W. D. Travis, J. B. Putnam, F. V. Fossella, R. W. Byhardt, and J. Y. Ro Oncodiagnosis Panel: 1999: Cancer of the Lung: Oncodiagnosis RadioGraphics, November 1, 2001; 21(6): 1573 - 1596. [Full Text] [PDF] |
||||
![]() |
K. Higashi, Y. Ueda, T. Sakuma, H. Seki, M. Oguchi, M. Taniguchi, S. Taki, H. Tonami, S. Katsuda, and I. Yamamoto Comparison of [18F]FDG PET and 201Tl SPECT in Evaluation of Pulmonary Nodules J. Nucl. Med., October 1, 2001; 42(10): 1489 - 1496. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Imdahl, S. Jenkner, I. Brink, E. Nitzsche, E. Stoelben, E. Moser, and J. Hasse Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 324 - 329. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. O. Wong, H. J. Dworkin, T. Hara, K. Inagaki, N. Kosaka, and T. Morita Clinical Skills in Conducting Research Studies on Clinical Applications of Oncologic PET J. Nucl. Med., May 1, 2001; 42(5): 826a - 827. [Full Text] |
||||
![]() |
M. Tatsumi, H. Kitayama, H. Sugahara, N. Tokita, H. Nakamura, Y. Kanakura, and T. Nishimura Whole-Body Hybrid PET with 18F-FDG in the Staging of Non-Hodgkin's Lymphoma J. Nucl. Med., April 1, 2001; 42(4): 601 - 608. [Abstract] [Full Text] |
||||
![]() |
R. R. Raylman Performance of a Dual, Solid-State Intraoperative Probe System with 18F, 99mTc, and 111In J. Nucl. Med., February 1, 2001; 42(2): 352 - 360. [Abstract] [Full Text] |
||||
![]() |
V. Kalff, R. J. Hicks, M. P. MacManus, D. S. Binns, A. F. McKenzie, R. E. Ware, A. Hogg, and D. L. Ball Clinical Impact of 18F Fluorodeoxyglucose Positron Emission Tomography in Patients With Non-Small-Cell Lung Cancer: A Prospective Study J. Clin. Oncol., January 1, 2001; 19(1): 111 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. R. Hirsch, W. A. Franklin, A. F. Gazdar, and P. A. Bunn Jr. Early Detection of Lung Cancer: Clinical Perspectives of Recent Advances in Biology and Radiology Clin. Cancer Res., January 1, 2001; 7(1): 5 - 22. [Abstract] [Full Text] |
||||
![]() |
P. M. Boiselle, A. Ernst, and D. D. Karp Lung Cancer Detection in the 21st Century: Potential Contributions and Challenges of Emerging Technologies Am. J. Roentgenol., November 1, 2000; 175(5): 1215 - 1221. [Full Text] [PDF] |
||||
![]() |
R. L. Thurer, A. Thorsen, J. A. Parker, and D. D. Karp FDG imaging of a pulmonary artery sarcoma Ann. Thorac. Surg., October 1, 2000; 70(4): 1414 - 1415. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |